Current treatment options for retinal angiomatous proliferans (RAP).
Retinal angiomatous proliferation (RAP) accounts for 12-15% of all patients with neovascular age-related macular degeneration (NV-AMD). However, this subtype is often excluded from clinical trials aimed at assessing the efficacy of various treatment options for NV-AMD. Thus, there are no established protocols for the management of RAP. This review of current literature on RAP compares the outcomes of various treatment options for this condition and highlights the lack of clinical trials and paucity of long-term data on this relatively common condition.
Gupta
Bhaskar
B
Ophthalmology Department, King's College Hospital, London, UK.
Jyothi
Sreedhar
S
Sivaprasad
Sobha
S
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000798:Angiomatosis / Q000628:therapy*; D020256:Choroidal Neovascularization / Q000628:therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D017075:Laser Coagulation / Q000379:methods; D008268:Macular Degeneration / Q000628:therapy*; D010778:Photochemotherapy / Q000379:methods; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A